| Literature DB >> 28509978 |
James J Wu1,2,3, Michael Seco1,2,3, Caroline Medi4,5, Chris Semsarian1,4,5, David R Richmond5, Joseph A Dearani6, Hartzell V Schaff6, Michael J Byrom2,3, Paul G Bannon7,8,9.
Abstract
Hypertrophic cardiomyopathy (HCM) is a genetically determined cardiac disease characterised by otherwise unexplained myocardial hypertrophy of the left ventricle, and may result in left ventricular outflow tract obstruction. It is the most common cause of sudden cardiac death in young adults due to arrhythmias. Septal myectomy is a surgical treatment for HCM with moderate to severe outflow tract obstruction, and is indicated for patients with severe symptoms refractory to medical therapy. The surgical approach involves obtaining access to the interventricular septum via transaortic, transapical or transmitral approaches, and excising a portion of the hypertrophied myocardium to relieve the outflow tract obstruction. Large, contemporary series from centres experienced in septal myectomy patients have demonstrated a low early mortality of <2 %, excellent long-term survival that matches the general population, and durable relief of symptoms.Entities:
Keywords: Alcohol septal ablation; Hypertrophic cardiomyopathy; Left ventricular outflow tract obstruction; Septal myectomy
Year: 2015 PMID: 28509978 PMCID: PMC5418425 DOI: 10.1007/s12551-014-0153-3
Source DB: PubMed Journal: Biophys Rev ISSN: 1867-2450